

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 4, 2004

-----  
Date of Report (Date of earliest event reported)

ORAGENICS, INC.

-----  
(Exact name of registrant as specified in its charter)

Florida                      333-100568                      59-3410522

-----  
(State or other jurisdiction      (Commission                      (IRS Employer  
of incorporation)              File Number)                      Identification No.)

12085 Research Drive  
Alachua, Florida 32615

-----  
(Address of principal executive offices including zip code)

(386) 418-4018

-----  
Registrant's telephone number, including area code

None

-----  
(Former name or former address, if changed since last report.)

=====

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

Exhibit No.	Description
-------------	-------------

-----

99.1	Press Release
------	---------------

ITEM 9. REGULATION FD DISCLOSURE

Oragenics, Inc. announces that it has licensed novel technology for which a Phase I SBIR award has been granted by the National Institute of Allergy and Infectious Diseases.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 4th day of March, 2004.

ORAGENICS, INC.  
(Registrant)

BY: /s/ Mento A. Soponis

-----  
Mento A. Soponis  
President, Principal  
Executive Officer and a  
member of the Board of  
Directors.

[LOGO]  
ORAGENICS

Contact:

Chuck Sponis  
Chief Executive Officer  
Oragenics, Inc.  
(386) 418-4018

For Media:

Joan Kureczka  
Kureczka/Martin Associates  
(415) 821-2413  
Jkureczka@aol.com

FOR IMMEDIATE RELEASE

Oragenics Licenses Novel Technology for Gene Target Identification  
with Broad Potential to Generate Products for Human  
Health and Other Applications

Company also receives Phase I SBIR Grant Supporting Applications of the  
Technology in Tuberculosis

ALACHUA, FL (March 4, 2004) - Oragenics, Inc. (OTC: OGEN; TSX-V:ORA.U) today announced that it has licensed from iviGene Corporation, also of Alachua, FL, applications of a novel technology that enables the rapid identification of potential therapeutic, vaccine or diagnostic targets implicated in the onset and progression of disease. Oragenics has gained exclusive worldwide rights to this broad platform technology in the areas of cancer and tuberculosis, as well as agricultural and other non-human uses. In return, iviGene will receive from Oragenics royalties on revenues from any products developed using the technology, including royalties on sublicense fees, milestone payments and future product sales.

The company also announced the receipt of a Phase I SBIR Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) supporting development of the technology to identify genes of Mycobacterium tuberculosis that are specifically induced during human infections with that pathogen. The grant, covering the period of March 1, 2004 to August 31, 2004 provides Oragenics with \$100,000 in research funding.

"This technology enables the simple, fast identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers and other diseases in humans and other living organisms, including plants," said Chuck Sponis, Oragenics' president and chief executive officer. "It offers Oragenics the potential to generate and develop a number of product candidates for future out-licensing to corporate partners, particularly in the area of cancer."

He continued, "Our Replacement Therapy product for preventing tooth decay and probiotic product for oral health are moving from R&D into clinical development and potential out-licensure. Thus we are ideally situated at this time to bring in new R&D technology to exploit our scientific team's talents. The potential that this target identification platform offers for generating a stream of new product opportunities makes its acquisition a great strategic step for Oragenics."

About the In-licensed Technology

The technology platform licensed by Oragenics represents novel methods of identifying genes that are expressed specifically during disease in affected humans or other living organisms. The basis of this platform is a method developed by iviGene co-founder and Oragenics' founder and chief scientific officer, Jeffrey D. Hillman, DMD, PhD, and University of Florida scientists, called in vivo induced antigen technology (IVIAT). IVIAT can quickly and easily identify in vivo induced genes in human infections without the use of animal models, facilitating the discovery of new targets for the development of vaccines, antimicrobials and diagnostics. Dr. Hillman and his collaborators have further developed methods based on this approach to create Change Mediated Antigen Technology (CMAT). CMAT can be used to identify gene targets associated with the onset and progression of cancerous processes and autoimmune diseases. It can also be used to identify novel genes in plant diseases, including genes

expressed by the pathogen when it causes the disease and genes expressed by the plant in response to the disease.

#### About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. The company's lead product is a novel oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The company is also developing a novel antibiotic with broad-spectrum activity against gram positive bacteria and a probiotic product aimed at maintaining oral health. The company is headquartered in Alachua, Florida. For more information about Oragenics, please consult the company's website at [www.oragenics.com](http://www.oragenics.com).

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions which do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (1) the ability to successfully complete development and commercialization of Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic, and probiotic product for oral health; (2) the ability to obtain substantial additional funding; (3) the ability to develop and commercialize products before competitors; (4) the ability to develop commercial products with the in-licensed technology; and (5) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

###